| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 449.7 | 641.6 | 514.3 |
| Other income | 7.5 | 8.5 | 1.8 |
| Total income | 457.2 | 650.1 | 516.1 |
| Profit before exceptional items & tax | 69.0 | 197.8 | 129.4 |
| Profit before tax | 69.0 | 197.8 | 129.4 |
| Net profit | 51.6 | 147.7 | 96.9 |
| Operating margin | 15.1% | 30.4% | 25.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -46.70% |
|---|---|
| Net profit, quarter on quarter | -65.10% |
| Revenue, year on year | -12.60% |
| Operating profit, year on year | -51.80% |
| Operating profit, quarter on quarter | -67.50% |
BSE results filing, NSE: NEULANDLAB. Figures extracted from the filing.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹19,424.00
- Market cap
- ₹24,921 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 50.1×Sector 47.2×
- Promoter holding
- 32.26%-0.36% QoQ
- FII holding
- 21.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Investor Presentation: Key Takeaways
Q2FY27 income Rs457.2 Cr (-11.4% YoY), PAT Rs51.1 Cr (-47.0%), EBITDA margin 22.9% on operating deleverage. H1FY27 income Rs1107.2 Cr (+35.6%), PAT Rs198.5 Cr (+80.2%). Capex-led R&D and peptide build-out.
Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.
Neuland Laboratories Other Announcement
Neuland Laboratories notified loss of 100 share certificates by shareholder Madan Mohan Singh. The company requested issuance of an entitlement letter in lieu of the lost certificates.
Neuland Laboratories Board Meeting Date
Neuland Laboratories will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Neuland Laboratories Business Update
Neuland Laboratories' Unit 3 manufacturing facility received an Establishment Inspection Report from the US FDA. The agency has officially closed the inspection.
Neuland Laboratories Other Announcement
Neuland Laboratories Ltd has submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Regulation 31.